ヘルスケア関連感染症診断薬市場：製品・サービス、疾患タイプ、エンドユーザー別-2025-2030年世界予測

ヘルスケア関連感染症診断薬市場は、2023年に40億4,000万米ドルと評価され、2024年には43億7,000万米ドルに達すると予測され、CAGR 8.35％で成長し、2030年には70億9,000万米ドルに達すると予測されています。

調査手法ヘルスケア関連感染症診断薬とは、病院や外来診療所などのヘルスケア環境で感染症を検出するために採用されるさまざまな検査や手法のことです。これらの診断の必要性は、患者の安全性に重大なリスクをもたらし、入院期間を延長させ、医療費を増大させる感染症を管理・制御する必要性から生じています。診断ツールの用途は、感染症の初期検出・診断から継続的なモニタリング・管理まで、さまざまな段階にわたる。主なエンドユーザーには、病院、診断ラボ、外来患者向けヘルスケア施設などがあり、迅速かつ正確な診断は、効果的な感染制御および予防戦略にとって極めて重要です。

市場の洞察によると、ヘルスケア関連感染症診断薬の成長の主な原動力は、ヘルスケア関連感染症（HAI）の蔓延の増加、診断技術の進歩、感染対策に対する意識の高まりです。最新のビジネスチャンスは、診断と治療に必要な時間を短縮する迅速診断キットの開発や、診断精度と効率を高めるための人工知能と機械学習の統合から生まれています。企業は、革新的な診断ソリューションの研究開発に投資し、ヘルスケア機関との提携を通じて市場でのプレゼンスを拡大することで、こうした機会を活用することができます。

しかし、同市場は、高度な診断ツールに関連する高コスト、規制上の課題、複雑な機器を操作する熟練者の必要性などの限界にも直面しています。さらに、新興・再興感染症の脅威は、診断法を最新の状態に保つための継続的な課題となっています。

革新的な研究開発分野には、遠隔地や資源が限られた環境における診断の有用性を高めるため、すぐに結果が得られるポイントオブケア診断薬の開発が含まれます。複数の病原体を同時に検査できるマルチプレックス診断薬の調査も、合理的で費用対効果の高い解決策を提供するものです。市場は依然としてダイナミックであり、進化する技術と新たな感染脅威への継続的な適応の必要性に焦点が当てられています。

市場力学：急速に進化するヘルスケア関連感染症診断薬市場の主要市場インサイトを公開

ヘルスケア関連感染症診断薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 集中型検査室から分散型ポイントオブケア検査への焦点のシフト
  • 感染症診断に関する研究資金の増加
• 市場抑制要因
  • ヘルスケア現場におけるHAI予防のための厳しい規制
  • HAIを管理するための高度なメカニズム
• 市場機会
  • ヘルスケア関連感染症患者の増加
  • 中低所得国での高い成長の可能性
  • HAI診断のためのPOC検査の普及拡大
• 市場の課題
  • 不十分な診療報酬
  • 高所得国におけるHAIの低い有病率

ポーターの5つの力：ヘルスケア関連感染症診断薬市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：ヘルスケア関連感染症診断薬市場における外部からの影響の把握

外部マクロ環境要因は、ヘルスケア関連感染症診断薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析ヘルスケア関連感染症診断薬市場における競合情勢の把握

ヘルスケア関連感染症診断薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスヘルスケア関連感染症診断薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、ヘルスケア関連感染症診断薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨ヘルスケア関連感染症診断薬市場における成功への道筋を描く

ヘルスケア関連感染症診断薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 集中型の検査室から分散型のポイントオブケア検査への重点の移行
    • 感染症診断に関する調査への資金提供の増加
  • 抑制要因
    • ヘルスケア現場における院内感染を防ぐための厳格な規制
    • HAIを制御するための洗練されたメカニズム
  • 機会
    • 医療関連感染症の対象患者の増加
    • 低・中所得国における高い成長可能性
    • HAI診断のためのPOC検査の普及率の向上
  • 課題
    • 不十分な払い戻し
    • 高所得国における院内感染の有病率の低さ
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 ヘルスケア関連感染症診断薬市場：製品・サービス別

• アッセイ、キット、試薬
• 機器
• サービスとソフトウェア

第7章 ヘルスケア関連感染症診断薬市場：疾患タイプ別

• クラミジア・トラコマティス性器感染症と淋病
• 肝炎
• 院内感染
• ヒト免疫不全ウイルス
• ヒトパピローマウイルス
• インフルエンザ
• 結核

第8章 ヘルスケア関連感染症診断薬市場：エンドユーザー別

• 学術調査機関
• 病院および臨床検査室
• 医師のオフィス
• リファレンスラボ

第9章 南北アメリカのヘルスケア関連感染症診断薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のヘルスケア関連感染症診断薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのヘルスケア関連感染症診断薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Becton, Dickinson and Company
• Bio-Rad Laboratories, Inc.
• Biomerieux SA
• Co-Diagnostics Inc.
• Danaher Corporation
• DiaSorin S.p.A.
• DNAe Group Holdings Ltd
• GNA Biosolutions GmbH
• Meridian Bioscience Inc. by SD Biosensor
• Qiagen N.V.
• Quidel Corporation
• Roche Holding AG
• Siemens Healthineers AG
• Thermo Fisher Scientific Inc.

LIST OF FIGURES

• FIGURE 1. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
• FIGURE 2. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET DYNAMICS
• TABLE 7. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ASSAYS, KITS & REAGENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY SERVICES & SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY CHLAMYDIA TRACHOMATIS GENITAL INFECTION & GONORRHEA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HEPATITIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITAL-ACQUIRED INFECTIONS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN IMMUNODEFICIENCY VIRUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HUMAN PAPILLOMAVIRUS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY INFLUENZA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY TUBERCULOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITAL & CLINICAL LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PHYSICIAN OFFICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 25. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 26. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 27. AMERICAS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 28. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 29. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 30. ARGENTINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 31. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 32. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 33. BRAZIL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 34. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 35. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 36. CANADA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 37. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 38. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 39. MEXICO HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 40. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 41. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 42. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 43. UNITED STATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 44. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 45. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 46. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 47. ASIA-PACIFIC HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 48. AUSTRALIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 49. AUSTRALIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 50. AUSTRALIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 51. CHINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 52. CHINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 53. CHINA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 54. INDIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 55. INDIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 56. INDIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. INDONESIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 58. INDONESIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 59. INDONESIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 60. JAPAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 61. JAPAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 62. JAPAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 63. MALAYSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 64. MALAYSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 65. MALAYSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. PHILIPPINES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 67. PHILIPPINES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 68. PHILIPPINES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 69. SINGAPORE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 70. SINGAPORE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 71. SINGAPORE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 72. SOUTH KOREA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 73. SOUTH KOREA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 74. SOUTH KOREA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 75. TAIWAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 76. TAIWAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 77. TAIWAN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 78. THAILAND HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 79. THAILAND HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 80. THAILAND HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. VIETNAM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 82. VIETNAM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 83. VIETNAM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 84. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 85. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 86. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 87. EUROPE, MIDDLE EAST & AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 88. DENMARK HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 89. DENMARK HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 90. DENMARK HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 91. EGYPT HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 92. EGYPT HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 93. EGYPT HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 94. FINLAND HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 95. FINLAND HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 96. FINLAND HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 97. FRANCE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 98. FRANCE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 99. FRANCE HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 100. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 101. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 102. GERMANY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. ISRAEL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 104. ISRAEL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 105. ISRAEL HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 106. ITALY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 107. ITALY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 108. ITALY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 109. NETHERLANDS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 110. NETHERLANDS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 111. NETHERLANDS HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 112. NIGERIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 113. NIGERIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 114. NIGERIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. NORWAY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 116. NORWAY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 117. NORWAY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 118. POLAND HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 119. POLAND HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 120. POLAND HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 121. QATAR HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 122. QATAR HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 123. QATAR HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. RUSSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 125. RUSSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 126. RUSSIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 127. SAUDI ARABIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 128. SAUDI ARABIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 129. SAUDI ARABIA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 130. SOUTH AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 131. SOUTH AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SOUTH AFRICA HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 133. SPAIN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 134. SPAIN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SPAIN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 136. SWEDEN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 137. SWEDEN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 138. SWEDEN HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. SWITZERLAND HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 140. SWITZERLAND HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 141. SWITZERLAND HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 142. TURKEY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 143. TURKEY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 144. TURKEY HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. UNITED ARAB EMIRATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED ARAB EMIRATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 147. UNITED ARAB EMIRATES HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 148. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY PRODUCT & SERVICE, 2018-2030 (USD MILLION)
• TABLE 149. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
• TABLE 150. UNITED KINGDOM HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 151. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 152. HEALTHCARE-ASSOCIATED INFECTIOUS DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2023

The Healthcare-associated Infectious Disease Diagnostics Market was valued at USD 4.04 billion in 2023, expected to reach USD 4.37 billion in 2024, and is projected to grow at a CAGR of 8.35%, to USD 7.09 billion by 2030.

Healthcare-associated infectious disease diagnostics refer to the variety of tests and methodologies employed to detect infections contracted in healthcare settings, such as hospitals and outpatient clinics. The necessity of these diagnostics arises from the need to control and manage infections that pose significant risks to patient safety, prolong hospital stays, and increase healthcare costs. The application of diagnostic tools spans various stages, from initial detection and diagnosis to ongoing monitoring and management of infectious diseases. Key end-users include hospitals, diagnostic laboratories, and outpatient healthcare facilities, where rapid and accurate diagnostics are crucial for effective infection control and prevention strategies.

Market insights indicate that the growth of healthcare-associated infectious disease diagnostics is predominantly driven by the increasing prevalence of healthcare-associated infections (HAIs), advancements in diagnostic technologies, and rising awareness of infection control practices. The latest opportunities emerge from the development of rapid diagnostic kits, which shorten the time needed for diagnosis and treatment, and the integration of artificial intelligence and machine learning to enhance diagnostic accuracy and efficiency. Companies can capitalize on these opportunities by investing in R&D for innovative diagnostic solutions and expanding their market presence through partnerships with healthcare institutions.

However, the market also faces limitations such as high costs associated with advanced diagnostic tools, regulatory challenges, and the need for skilled personnel to operate complex equipment. Additionally, the threat of emerging and re-emerging infectious diseases poses continuous challenges to keeping diagnostic methods up-to-date.

Areas for innovation and research include the development of point-of-care diagnostics that provide immediate results, enhancing the utility of diagnostics in remote or resource-limited settings. Research into multiplex diagnostics, which can simultaneously test for multiple pathogens, offers another avenue for streamlined and cost-effective solutions. The market remains dynamic, with a focus on evolving technologies and the need for continual adaptation to emerging infectious threats, which underscores the critical role of strategic innovation for sustained business growth.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Healthcare-associated Infectious Disease Diagnostics Market

The Healthcare-associated Infectious Disease Diagnostics Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Shift in focus from centralized laboratories to decentralized point-of-care testing
  • Growth in funding for research on infectious disease diagnostics
• Market Restraints
  • Stringent regulations to prevent HAIs in healthcare settings
  • Sophisticated mechanisms available to control HAIs
• Market Opportunities
  • Increase in target patients with healthcare-associated infections
  • High growth potential in low and middle-income countries
  • Growing penetration of POC tests to diagnose HAIs
• Market Challenges
  • Inadequate reimbursements
  • Low prevalence of HAIs in high-income nations

Porter's Five Forces: A Strategic Tool for Navigating the Healthcare-associated Infectious Disease Diagnostics Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Healthcare-associated Infectious Disease Diagnostics Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Healthcare-associated Infectious Disease Diagnostics Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Healthcare-associated Infectious Disease Diagnostics Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Healthcare-associated Infectious Disease Diagnostics Market

A detailed market share analysis in the Healthcare-associated Infectious Disease Diagnostics Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Healthcare-associated Infectious Disease Diagnostics Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Healthcare-associated Infectious Disease Diagnostics Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Healthcare-associated Infectious Disease Diagnostics Market

A strategic analysis of the Healthcare-associated Infectious Disease Diagnostics Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Healthcare-associated Infectious Disease Diagnostics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Biomerieux SA, Co-Diagnostics Inc., Danaher Corporation, DiaSorin S.p.A., DNAe Group Holdings Ltd, GNA Biosolutions GmbH, Meridian Bioscience Inc. by SD Biosensor, Qiagen N.V., Quidel Corporation, Roche Holding AG, Siemens Healthineers AG, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Healthcare-associated Infectious Disease Diagnostics Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product & Service, market is studied across Assays, Kits & Reagents, Instruments, and Services & Software.
• Based on Disease Type, market is studied across Chlamydia Trachomatis Genital Infection & Gonorrhea, Hepatitis, Hospital-Acquired Infections, Human Immunodeficiency Virus, Human Papillomavirus, Influenza, and Tuberculosis.
• Based on End-user, market is studied across Academic & Research Institutes, Hospital & Clinical Laboratories, Physician Offices, and Reference Laboratories.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Shift in focus from centralized laboratories to decentralized point-of-care testing
    • 5.1.1.2. Growth in funding for research on infectious disease diagnostics
  • 5.1.2. Restraints
    • 5.1.2.1. Stringent regulations to prevent HAIs in healthcare settings
    • 5.1.2.2. Sophisticated mechanisms available to control HAIs
  • 5.1.3. Opportunities
    • 5.1.3.1. Increase in target patients with healthcare-associated infections
    • 5.1.3.2. High growth potential in low and middle-income countries
    • 5.1.3.3. Growing penetration of POC tests to diagnose HAIs
  • 5.1.4. Challenges
    • 5.1.4.1. Inadequate reimbursements
    • 5.1.4.2. Low prevalence of HAIs in high-income nations
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Healthcare-associated Infectious Disease Diagnostics Market, by Product & Service

• 6.1. Introduction
• 6.2. Assays, Kits & Reagents
• 6.3. Instruments
• 6.4. Services & Software

7. Healthcare-associated Infectious Disease Diagnostics Market, by Disease Type

• 7.1. Introduction
• 7.2. Chlamydia Trachomatis Genital Infection & Gonorrhea
• 7.3. Hepatitis
• 7.4. Hospital-Acquired Infections
• 7.5. Human Immunodeficiency Virus
• 7.6. Human Papillomavirus
• 7.7. Influenza
• 7.8. Tuberculosis

8. Healthcare-associated Infectious Disease Diagnostics Market, by End-user

• 8.1. Introduction
• 8.2. Academic & Research Institutes
• 8.3. Hospital & Clinical Laboratories
• 8.4. Physician Offices
• 8.5. Reference Laboratories

9. Americas Healthcare-associated Infectious Disease Diagnostics Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Healthcare-associated Infectious Disease Diagnostics Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Healthcare-associated Infectious Disease Diagnostics Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Becton, Dickinson and Company
• 3. Bio-Rad Laboratories, Inc.
• 4. Biomerieux SA
• 5. Co-Diagnostics Inc.
• 6. Danaher Corporation
• 7. DiaSorin S.p.A.
• 8. DNAe Group Holdings Ltd
• 9. GNA Biosolutions GmbH
• 10. Meridian Bioscience Inc. by SD Biosensor
• 11. Qiagen N.V.
• 12. Quidel Corporation
• 13. Roche Holding AG
• 14. Siemens Healthineers AG
• 15. Thermo Fisher Scientific Inc.